Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 22, 2010

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hemophilia B
Interventions
GENETIC

Gene Transfer

Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant

DRUG

scAAV2/8-LP1-hFIXco

Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.

Trial Locations (8)

15213

Hemophilia Center of Western Pennsylvania, Pittsburgh

38119

St. Jude Children's Research Hospital, Memphis

40536

University of Kentucky, Lexington

76508

Scott and White Memorial Hospital, Temple

94305

Stanford Medical School, Stanford

97239

Oregon Health and Science University, Portland

75390-9063

University of Texas Southwestern, Dallas

Unknown

Katharine Dormandy Haemophilia Centre and Haemostasis Unit, University College of London, London

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Hemophilia of Georgia, Inc.

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

University College, London

OTHER

lead

St. Jude Children's Research Hospital

OTHER

NCT00979238 - Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B | Biotech Hunter | Biotech Hunter